Management of hyperglycaemia guidance for people living with type 2 diabetes published
Published on 14 October 2022
Weight loss and blood glucose lowering treatments highlighted in report presented at the recent European Association for the Study of Diabetes conference
New recommendations on how to improve equity of care and reviews on how social determinants of health impact the management of hyperglycaemia in people living with type 2 diabetes.
Hyperglycaemia is a common complication of both type 1 and type 2 diabetes caused when blood sugar levels are too high. The Management of hyperglycemia in type 2 diabetes, 2022. A consensus report has been published by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
The report was presented at the 58th European Association for the Study of Diabetes (EASD) Annual Meeting 2022.
The report was prepared by an international committee of experts that include John B. Buse, MD, PhD, (University of North Carolina School of Medicine, Chapel Hill, NC); Melanie J. Davies, CBE, MBChB, MD, FRCP, FRCGP, FMedSciat (Leicester Diabetes Centre, Leicester, UK); and their colleagues.
The report paid attention to the importance of weight loss and the use of evidence from randomised controlled trials on blood sugar-lowering medications to support evidence on losing and gaining weight.
Dr Robert Gabbay, Chief Scientific and Medical Officer for the ADA, said: “We are excited to share an updated consensus report on the management of hyperglycaemia in type 2 diabetes.
“This is a wide-ranging consensus report that has several new features. It not only speaks of what needs to be done, but it also has a section on how to implement those changes.”
In June 2022, a first draft of the guidance was presented at ADA’s 82nd Scientific Sessions, allowing the authors to receive constructive feedback.
Delegates recommended that the report should focus more on person-centred care, equity of care and managing weight loss.
The report said: “The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycaemia in type 2 diabetes in adults, published since 2006 and last updated in 2019.
“The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviours, including sleep.
“There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease.”
The report concluded: “We must establish and re fine quality improvement efforts in diabetes care at the local level to equitably implement evidence-based interventions for the benefit of all people with type 2 diabetes.
Read more about type 2 diabetes
Support DRWF by making a donation here
Find out more about DRWF-funded research here
Find out more about DRWF fundraising here
To receive the charity’s latest bulletins as they become available, please sign up here
Read DRWF diabetes information leaflets here
Join the Diabetes Wellness Network here
I would like to make a regular donation of
I would like to make a single donation of